Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.

Novo Nordisk’s insulin brand Mixtard will continue to be available in vials, the Danish healthcare company clarified, even as it phases out its penfill. The penfill is being phased out as part of ...

Novo Nordisk clarifies Human Mixtard penfill to be replaced with injectables: Our Bureau, Bengaluru Wednesday, April 23, 2025, 13:30 Hrs [IST] Denmark-based global pharma major, N ...

Ellison says the settlement requires Novo Nordisk to provide insulin products—including ... per monthly prescription (3 vials or 2 packs of pens) for customers paying with cash.

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Novo Nordisk will continue offering its top-selling insulin brand, Mixtard, in vial form in India, despite phasing out ...

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic Wegovy.

Also read: Novo Nordisk to continue India's largest ... This may limit the access further as insulin delivery from pen devices is preferred by a huge majority of diabetics over vials injected ...

Besides by market capitalization, Novo Nordisk is largest in Denmark. Pen insulin range of Novo Nordisk is convenient, accurate, not painful during administration, portable making it extremely handy ...

In September 2024, to launch a smart app for insulin FlexTouch pens, Mallya, planned by Novo Nordisk Korea. Mallya is designed to work with FlexTouch pens used for treatments like Fiasp ...

A partial phase out of a top insulin product by Danish drug maker Novo Nordisk may open a bounty for Eris Pharma and its ...